Novo Nordisk A/S (NVO) Stock Forecast & Price Target

$42.21 +1.19 (+2.91%)

Closing price 03:59 PM Eastern

Extended Trading

$42.18 -0.03 (-0.08%)

As of 04:06 PM Eastern

Compare

Novo Nordisk A/S - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Hold

Based on 23 Analyst Ratings

Sell
1

Hold
18

Buy
4

Based on 23 Wall Street analysts who have issued ratings for Novo Nordisk A/S in the last 12 months, the stock has a consensus rating of "Hold." Out of the 23 analysts, 1 has given a sell rating, 18 have given a hold rating, and 4 have given a buy rating for NVO.

Consensus Price Target

$65.56
55.31% Upside

According to the 23 analysts' twelve-month price targets for Novo Nordisk A/S, the average price target is $65.56. The highest price target for NVO is $175.00, while the lowest price target for NVO is $40.00. The average price target represents a forecasted upside of 55.31% from the current price of $42.21.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for NVO and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Novo Nordisk A/S and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

NVO Analyst Ratings Over Time

Type	Current Forecast 6/9/25 to 6/9/26	1 Month Ago 5/10/25 to 5/10/26	3 Months Ago 3/11/25 to 3/11/26	1 Year Ago 6/9/24 to 6/9/25
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	1 Strong Buy rating(s)
Buy	4 Buy rating(s)	4 Buy rating(s)	4 Buy rating(s)	4 Buy rating(s)
Hold	18 Hold rating(s)	18 Hold rating(s)	19 Hold rating(s)	5 Hold rating(s)
Sell	1 Sell rating(s)	1 Sell rating(s)	0 Sell rating(s)	2 Sell rating(s)
Consensus Price Target	$65.56	$65.56	$49.93	$128.00
Forecasted Upside	55.31% Upside	42.47% Upside	28.63% Upside	69.64% Upside
Consensus Rating	Hold	Hold	Hold	Hold

NVO Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

NVO Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Novo Nordisk A/S Stock vs. The Competition

Type	Novo Nordisk A/S	Medical Companies	Broader Market
Consensus Rating Score	2.13	2.30	2.52
Consensus Rating	Hold	Hold	Moderate Buy
Predicted Upside	58.73% Upside	683.69% Upside	16.09% Upside
News Sentiment Rating	Positive News See Recent NVO News	Neutral News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
5/12/2026	Citigroup 4 of 5 stars		Reiterated Rating	Neutral
4/22/2026	Weiss Ratings Not Rated		Downgrade	Hold (C-) ➝ Sell (D+)
3/26/2026	Wolfe Research 3 of 5 stars		Initiated Coverage	Peer Perform
3/18/2026	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Initiated Coverage	Outperform	$175.00	+367.93%
3/10/2026	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Strong Sell ➝ Hold
3/10/2026	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Buy ➝ Hold	$42.00	+5.60%
3/3/2026	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Thibault Boutherin Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Underweight ➝ Equal Weight	$40.00	+5.99%
3/2/2026	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	James Quigley Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$63.00 ➝ $41.00	+9.34%
2/24/2026	Nordea Equity Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Hold
2/24/2026	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Richard Vosser Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Overweight ➝ Neutral
Trump's gold order: the announcement they won't put on the front page (Ad) On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free. Request the free guide in 30 seconds and get positioned now
2/24/2026	Kepler Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Buy ➝ Hold
2/23/2026	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Buy ➝ Hold
2/12/2026	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Michael Leuchten Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Underperform ➝ Hold
2/5/2026	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Evan Seigerman Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Market Perform
1/9/2026	CICC Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Initiated Coverage	Outperform	$73.50	+28.19%
12/10/2025	HSBC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Rajesh Kumar Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Hold	$54.00	+16.58%
12/8/2025	Argus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	John Eade Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold
9/17/2025	Berenberg Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Kerry Holford Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Hold ➝ Buy
9/16/2025	Rothschild & Co Redburn Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Neutral ➝ Buy
8/22/2025	Dbs Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Strong Sell ➝ Hold
8/13/2025	BNP Paribas Exane Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Underperform ➝ Neutral
8/5/2025	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Matthew Weston Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade	Buy ➝ Neutral
7/30/2025	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Emily Field Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Overweight ➝ Equal Weight
4/17/2025	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Seamus Fernandez Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
3/3/2025	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Buy ➝ Hold
11/6/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Overweight	$160.00 ➝ $160.00	+49.39%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 03:55 PM ET.

Should I Buy Novo Nordisk A/S Stock? NVO Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, June 5, 2026. Please send any questions or comments about these Novo Nordisk A/S pros and cons to contact@marketbeat.com.

Novo Nordisk A/S
Bull Case

Here are some ways that investors could benefit from investing in Novo Nordisk:

The current stock price is around $46, which may present a buying opportunity for investors looking for growth in the pharmaceutical sector.
Recent reports indicate a surge in demand for the Wegovy pill, with over 2 million prescriptions since January, suggesting strong market potential and revenue growth.
The company has a solid net margin, indicating efficient management and profitability, which can lead to higher returns for investors.
Analysts have a consensus rating of "Hold" with a target price of approximately $65.56, suggesting potential upside for the stock.
With a return on equity of over 63%, Novo Nordisk demonstrates effective use of shareholder funds, which is a positive indicator for investors.

Novo Nordisk A/S
Bear Case

Investors should be bearish about investing in Novo Nordisk for these reasons:

Several analysts have downgraded their ratings recently, indicating a cautious outlook on the stock's performance.
The stock has experienced fluctuations, with a 12-month high of $81.44 and a low of $35.12, reflecting volatility that may concern risk-averse investors.
With a price-to-earnings ratio around 10.80, some investors may view the stock as overvalued compared to industry peers.
The company's debt-to-equity ratio of 0.59 suggests a moderate level of debt, which could pose risks if market conditions change.
Recent downgrades from firms like TD Cowen and Goldman Sachs indicate a shift in sentiment that could impact investor confidence.

NVO Forecast - Frequently Asked Questions

According to the research reports of 23 Wall Street equities research analysts, the average twelve-month stock price forecast for Novo Nordisk A/S is $65.56, with a high forecast of $175.00 and a low forecast of $40.00.

23 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Novo Nordisk A/S in the last twelve months. There is currently 1 sell rating, 18 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" NVO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVO, but not buy additional shares or sell existing shares.

According to analysts, Novo Nordisk A/S's stock has a predicted upside of 55.31% based on their 12-month stock forecasts.

Over the previous 90 days, Novo Nordisk A/S's stock had 2 downgrades and 1 upgrade by analysts.

Novo Nordisk A/S has been rated by research analysts at Citigroup, Sanford C. Bernstein, Weiss Ratings, and Wolfe Research in the past 90 days.

Analysts like Novo Nordisk A/S less than other "medical" companies. The consensus rating score for Novo Nordisk A/S is 2.13 while the average consensus rating score for "medical" companies is 2.30. Learn more on how NVO compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Novo Nordisk A/S Recommendations

This page (NYSE:NVO) was last updated on 6/9/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Novo Nordisk A/S (NVO) Stock Forecast & Price Target

Novo Nordisk A/S - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

NVO Analyst Ratings Over Time

NVO Analyst Recommendations By Month

NVO Price Targets by Month

Novo Nordisk A/S Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

Should I Buy Novo Nordisk A/S Stock? NVO Pros and Cons Explained

Novo Nordisk A/S
Bull Case

Novo Nordisk A/S
Bear Case

NVO Forecast - Frequently Asked Questions

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Novo Nordisk A/S Recommendations

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Novo Nordisk A/S (NVO) Stock Forecast & Price Target

Novo Nordisk A/S - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

NVO Analyst Ratings Over Time

NVO Analyst Recommendations By Month

NVO Price Targets by Month

Novo Nordisk A/S Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

Should I Buy Novo Nordisk A/S Stock? NVO Pros and Cons Explained

Novo Nordisk A/S Bull Case

Novo Nordisk A/S Bear Case

NVO Forecast - Frequently Asked Questions

What is Novo Nordisk A/S's forecast for 2026?

Should I buy or sell Novo Nordisk A/S stock right now?

Does Novo Nordisk A/S's stock price have much upside?

Has Novo Nordisk A/S been upgraded or downgraded by Wall Street analysts recently?

What analysts cover Novo Nordisk A/S?

Do Wall Street analysts like Novo Nordisk A/S more than its competitors?

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Novo Nordisk A/S Recommendations

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

Novo Nordisk A/S
Bull Case

Novo Nordisk A/S
Bear Case